ZDHHC4 and neoplasm: In a homozygous mouse model, this vaccine enhanced cytotoxic T lymphocyte activity, disrupted tumor vasculature, and effectively suppressed colon cancer progression, thereby establishing an experimental foundation for DC1-based immunotherapy in CRC [162].